TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34539429

Group type: EXPERIMENTAL
Intervention: Marathon training characteristics and anthropometric measurements
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Physiological determinants
Number of subjects: 45
Study: 34539455

Group type: EXPERIMENTAL
Intervention: Video Game requiring Emotional Regulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34539521

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 114
Study: 34539546

Group type: EXPERIMENTAL
Intervention: Intraplaque enhancement
Number of subjects: 0
Study: 34539750

Group type: EXPERIMENTAL
Intervention: CXCL16 T123V181 haplotype
Number of subjects: 1620
Study: 34539759

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34539777

Group type: EXPERIMENTAL
Intervention: Increased degree values in the left thalamus
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Increased degree values in the left cerebellum Crus I
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Decreased degree values in the left dorsolateral prefrontal cortex
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Decreased degree values in the right precuneus
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Decreased degree values in the left postcentral gyrus
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SVM classification analysis
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Altered degree values within and outside the CSTC circuit
Number of subjects: 78
Study: 34540013

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy plus apatinib (250 mg/day for 28 days)
Number of subjects: 30
Study: 34540651

Group type: EXPERIMENTAL
Intervention: Integrated genomic characterization by the Cancer Genome Atlas (TCGA) defining four distinct endometrial cancer subgroups (POLE mutated, microsatellite instability, low copy number, and high copy number)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorporation of molecular alterations into established clinicopathologic risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular profiling for tailoring adjuvant therapy in the high-intermediate-risk group
Number of subjects: 0
Study: 34540696

Group type: EXPERIMENTAL
Intervention: Chidamide, decitabine, cytarabine, idarubicin, and granulocyte-colony stimulating factor (CDIAG regimen)
Number of subjects: 35
Study: 34540697

Group type: EXPERIMENTAL
Intervention: Low-dose apatinib combined with S-1
Number of subjects: 30
Study: 34540703

Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal irradiation (18 Gy)
Number of subjects: 28
Study: 34540877

Group type: EXPERIMENTAL
Intervention: N247 nutraceutical formula
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 34540919

Group type: EXPERIMENTAL
Intervention: Aspirin for primary prevention of cardiovascular disease
Number of subjects: 0
Study: 34541016

Group type: EXPERIMENTAL
Intervention: BTB autograft
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Soft tissue autograft
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Combined medial and lateral meniscal repairs
Number of subjects: 646

Group type: COMPARATOR
Intervention: Isolated medial meniscal repairs
Number of subjects: 646

Group type: COMPARATOR
Intervention: Isolated lateral meniscal repairs
Number of subjects: 646

Group type: COMPARATOR
Intervention: Graft type
Number of subjects: 646
Study: 34541429

Group type: EXPERIMENTAL
Intervention: Surgery or medical treatments for diverticular disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical treatments, interventional radiology, and surgery
Number of subjects: 0
Study: 34541886

Group type: EXPERIMENTAL
Intervention: Cytotoxic edema on MRI
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: MRI findings of hemorrhage
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: ADC values
Number of subjects: 161
Study: 34541899

Group type: EXPERIMENTAL
Intervention: Rho GTPase signaling
Number of subjects: 0
Study: 34542347

Group type: EXPERIMENTAL
Intervention: AAC Plus
Number of subjects: 0
Study: 34542729

Group type: EXPERIMENTAL
Intervention: Arterial stiffness measures (pulse wave velocity, augmentation index) and HRV indices
Number of subjects: 304

Group type: COMPARATOR
Intervention: HRV measure (parasympathetic function)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Hemoglobin A1c
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Brachial distensibility
Number of subjects: 304
Study: 34542871

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa animal component-free
Number of subjects: 167
Study: 34543230

Group type: EXPERIMENTAL
Intervention: StayWell SMS text messaging intervention
Number of subjects: 193
Study: 34543383

Group type: EXPERIMENTAL
Intervention: Uproleselan (10 mg/kg twice daily) plus MEC (mitoxantrone, etoposide, and cytarabine)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Uproleselan (10 mg/kg twice daily) plus cytarabine and idarubicin (7 + 3)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Uproleselan added to chemotherapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: E-selectin expression >10% in R/R cohort
Number of subjects: 66
Study: 34543477

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (35 cycles)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based, four to six cycles)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 40
Study: 34543753

Group type: EXPERIMENTAL
Intervention: Preoperative negative polymerase chain reaction test for COVID-19
Number of subjects: 111
Study: 34543759

Group type: EXPERIMENTAL
Intervention: Seropositive HCWs
Number of subjects: 44698

Group type: EXPERIMENTAL
Intervention: Seropositive HCWs from dedicated COVID-19 wards
Number of subjects: 44698

Group type: EXPERIMENTAL
Intervention: Frontline HCWs
Number of subjects: 44698

Group type: EXPERIMENTAL
Intervention: Seropositive HCWs after 4-6 months
Number of subjects: 44698

Group type: COMPARATOR
Intervention: Seroreverted participants
Number of subjects: 44698
Study: 34544034

Group type: EXPERIMENTAL
Intervention: Digital handheld hydrogen breath monitor (GIMate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: FDA-cleared device (H2 Check)
Number of subjects: 31
Study: 34544050

Group type: EXPERIMENTAL
Intervention: Commercial ENDS devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-menthol and menthol cigarettes
Number of subjects: 0
Study: 34544269

Group type: EXPERIMENTAL
Intervention: Dual compartment suppositories
Number of subjects: 16
Study: 34544430

Group type: EXPERIMENTAL
Intervention: High-fat meal challenge (50 g fat)
Number of subjects: 35
Study: 34544675

Group type: EXPERIMENTAL
Intervention: COPPS risk predictors assessment at baseline
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: COPPS
Number of subjects: 177
Study: 34544679

Group type: EXPERIMENTAL
Intervention: Chatbot intervention for stress, sleep, and feeding
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chatbot intervention for stress
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chatbot intervention for feeding
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chatbot intervention for sleep
Number of subjects: 45
Study: 34545357

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34545967

Group type: EXPERIMENTAL
Intervention: Major hepatectomy (MHx)
Number of subjects: 0
Study: 34546172

Group type: EXPERIMENTAL
Intervention: Quantitative surveys and telephone interviews conducted in 2021, with follow-ups in 2022 and 2023.
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Discrete choice experiment with a subsample of participants.
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: In-depth interviews with participants who have moved within 6 months and follow-up interviews 12 months later.
Number of subjects: 2800
Study: 34547326

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid (TUDCA)
Number of subjects: 0
Study: 34547521

Group type: EXPERIMENTAL
Intervention: Romosozumab (12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romosozumab (12 months) followed by alendronate (24 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate only (24 months)
Number of subjects: 0
Study: 34547927

Group type: EXPERIMENTAL
Intervention: Penumbra System
Number of subjects: 650
Study: 34548038

Group type: EXPERIMENTAL
Intervention: Mighty Mums intervention (motivational talks, physical and nutritional activities)
Number of subjects: 1301
Study: 34548042

Group type: EXPERIMENTAL
Intervention: Methamphetamine use
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Polysubstance use (heroin, methamphetamine, alcohol)
Number of subjects: 44
Study: 34548050

Group type: EXPERIMENTAL
Intervention: Wasting (weight-for-length Z-score < -2)
Number of subjects: 6567

Group type: EXPERIMENTAL
Intervention: Stunting (length-for-age Z-score < -2)
Number of subjects: 6567

Group type: EXPERIMENTAL
Intervention: Concurrent wasting-stunting
Number of subjects: 6567

Group type: EXPERIMENTAL
Intervention: Risk factors for wasting and stunting
Number of subjects: 6567

Group type: EXPERIMENTAL
Intervention: Prior episodes of wasting and stunting
Number of subjects: 6567

Group type: EXPERIMENTAL
Intervention: Prior episodes of stunting
Number of subjects: 6567
Study: 34548198

Group type: COMPARATOR
Intervention: NR-Minor
Number of subjects: 645

Group type: COMPARATOR
Intervention: NR-Normal
Number of subjects: 645

Group type: COMPARATOR
Intervention: Possible ABMR
Number of subjects: 645

Group type: COMPARATOR
Intervention: ABMR
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: TCMR and Early-injury
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: NR-Minor and ABMR scores
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: MMDx ABMR
Number of subjects: 645
Study: 34548240

Group type: EXPERIMENTAL
Intervention: Current Hormone Replacement Therapy (HRT)
Number of subjects: 689

Group type: COMPARATOR
Intervention: Never HRT
Number of subjects: 689
Study: 34548321

Group type: EXPERIMENTAL
Intervention: LY3200882 monotherapy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: LY3200882 in combination therapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: LY3200882
Number of subjects: 139
Study: 34548324

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition administered in the first 7 days of postnatal life
Number of subjects: 16292

Group type: COMPARATOR
Intervention: No parenteral nutrition
Number of subjects: 16292
Study: 34548350

Group type: EXPERIMENTAL
Intervention: Habitual physical activity measured by accelerometry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Registry data on physical function (Danish Cerebral Palsy Follow-Up Programme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validated proxy-reported questionnaires on quality of life (Paediatric Quality of Life Inventory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paediatric Outcomes Data Collection Instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplementary questions regarding sleep, screen time, and socioeconomic status
Number of subjects: 0
Study: 34548371

Group type: EXPERIMENTAL
Intervention: Mental health assessment through self-report instruments and diagnostic interviews
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) assessment
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Exploration of mechanisms linking personality and perception of pandemic consequences
Number of subjects: 1200
Study: 34548595

Group type: EXPERIMENTAL
Intervention: Poseltinib
Number of subjects: 0
Study: 34549372

Group type: EXPERIMENTAL
Intervention: Family-based behavioral treatment (FBT)
Number of subjects: 241
Study: 34549906

Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous stem cell transplantation (ASCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New treatment combinations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frontline ASCT
Number of subjects: 0
Study: 34550079

Group type: EXPERIMENTAL
Intervention: Activity tracker-guided exercise program (arm B and C)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Personalized weekly targets for physical activity (arm C)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard care (arm A)
Number of subjects: 201
Study: 34550085

Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic (MET)-2, daily orally administered capsule containing 40 bacterial strains for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo, matching placebo for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Microbial Ecosystem Therapeutic (MET)-2
Number of subjects: 60
Study: 34550088

Group type: EXPERIMENTAL
Intervention: Joy Luck Academy (culturally sensitive social support intervention)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (educational information)
Number of subjects: 168
Study: 34550442

Group type: EXPERIMENTAL
Intervention: Telemedicine (TME)
Number of subjects: 689
Study: 34550527

Group type: EXPERIMENTAL
Intervention: Structural barriers to physical activity
Number of subjects: 1299

Group type: EXPERIMENTAL
Intervention: Younger age, higher BMI, lower educational level, no current work activity, co-morbidities, lacking physicians' exercise counseling
Number of subjects: 1299
Study: 34550528

Group type: EXPERIMENTAL
Intervention: DiCART™ device for CRT measurement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Venous and arterial occlusion tests
Number of subjects: 20
Study: 34550633

Group type: EXPERIMENTAL
Intervention: TOP2 poison chemotherapy
Number of subjects: 12
Study: 34550754

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34550757

Group type: EXPERIMENTAL
Intervention: Poziotinib treatment
Number of subjects: 30
Study: 34551181

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: MMF-free regimen
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Higher trough MMF concentrations
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (non-KTRs)
Number of subjects: 225
Study: 34551219

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 34551220

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 34551342

Group type: EXPERIMENTAL
Intervention: Patient navigation program
Number of subjects: 60
Study: 34551507

Group type: EXPERIMENTAL
Intervention: Pacritinib
Number of subjects: 189

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 189
Study: 34551725

Group type: EXPERIMENTAL
Intervention: Veterans Administration Video Connect (VVC)
Number of subjects: 45
Study: 34551738

Group type: EXPERIMENTAL
Intervention: Deep learning model for detecting shallow ACD
Number of subjects: 3753

Group type: EXPERIMENTAL
Intervention: Deep learning model
Number of subjects: 3753
Study: 34551765

Group type: EXPERIMENTAL
Intervention: Optimised participant information sheets developed through user testing
Number of subjects: 27805

Group type: COMPARATOR
Intervention: Routine information sheets generated by research teams
Number of subjects: 27805
Study: 34551886

Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg daily for days 1 to 28), Pomalidomide (daily for days 1 to 21), Dexamethasone (weekly for each 28-day cycle)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Venetoclax (400 mg daily for days 1 to 28)
Number of subjects: 8
Study: 34551940

Group type: EXPERIMENTAL
Intervention: Maternal vitamin B exposure (exact dosage and duration not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain MRI (structural T1, resting-state functional connectivity, diffusion tensor imaging)
Number of subjects: 0
Study: 34552007

Group type: EXPERIMENTAL
Intervention: Epigenetic inhibitors, specific agents not mentioned, duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immune checkpoint inhibitors, specific agents not mentioned, duration not specified.
Number of subjects: 0
Study: 34552462

Group type: EXPERIMENTAL
Intervention: VN-NDT
Number of subjects: 30
Study: 34552538

Group type: EXPERIMENTAL
Intervention: ARTISAN intervention (5-week, 15-hour participatory art and group-based intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 34552548

Group type: EXPERIMENTAL
Intervention: Mechanical Wrist Traction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34552549

Group type: EXPERIMENTAL
Intervention: Mobility Rehab System for Mobility Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34552864

Group type: EXPERIMENTAL
Intervention: ACY-241 (citarinostat) at 180 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ACY-241 (citarinostat) at 360 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ACY-241 (citarinostat) at 480 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nivolumab at 240 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 17
Study: 34552937

Group type: EXPERIMENTAL
Intervention: Ayurvedic Nutritional Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Nutritional Therapy including Low-FODMAP Diet
Number of subjects: 0
Study: 34552943

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34553156

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg administered in early follicular phase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg administered in midluteal phase
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg administered in late follicular phase
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 34553161

Group type: EXPERIMENTAL
Intervention: Elagolix 300 mg twice daily with estradiol 1 mg/norethindrone acetate 0.5 mg once daily
Number of subjects: 786

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786
Study: 34553294

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34553506

Group type: EXPERIMENTAL
Intervention: REACH referral rule
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: CARE referral rule
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Composite referral rule for IRD
Number of subjects: 250
Study: 34553956

Group type: EXPERIMENTAL
Intervention: Neural responsivity to thin models and high-calorie foods
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High-calorie food-specific go/no-go paradigm
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 88
Study: 34554139

Group type: EXPERIMENTAL
Intervention: High-priority research questions
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Medium-priority research questions
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Low-priority research questions
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Consensus on research questions
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Understanding functional outcomes after injury
Number of subjects: 597
Study: 34554228

Group type: EXPERIMENTAL
Intervention: Multiplex polymerase chain reaction plus phenotypic detection algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine cultures
Number of subjects: 0
Study: 34554440

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Changes in appetite
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Changes in taste
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Increased sensation for sweet taste
Number of subjects: 146

Group type: COMPARATOR
Intervention: Changes in taste and smell perceptions
Number of subjects: 146
Study: 34554571

Group type: EXPERIMENTAL
Intervention: Sulthiame (STM)
Number of subjects: 355
Study: 34554584

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 26
Study: 34554686

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Intravenous dexamethasone
Number of subjects: 1345
Study: 34554689

Group type: EXPERIMENTAL
Intervention: Viable Disc Tissue Allograft Supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34554698

Group type: EXPERIMENTAL
Intervention: Pain Sensitivity Questionnaire (PSQ)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Composite pain score (calculated from PSQ, light unpleasantness threshold, and interaction between gender and eye color)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sensitivity to unpleasantness of sound
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sensitivity to unpleasantness of light
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Younger age and dark eyes
Number of subjects: 85
Study: 34555181

Group type: EXPERIMENTAL
Intervention: School-based physical activity interventions
Number of subjects: 66752
Study: 34555420

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally and misoprostol 800 mcg buccally dispensed by mail-order pharmacy after in-person clinical assessment
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally and misoprostol 800 mcg buccally dispensed by mail-order pharmacy
Number of subjects: 240
Study: 34555554

Group type: EXPERIMENTAL
Intervention: Racing thoughts at bedtime in insomnia disorder
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Racing thoughts at bedtime
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rumination and worry
Number of subjects: 72
Study: 34555876

Group type: EXPERIMENTAL
Intervention: 4K vision system
Number of subjects: 29

Group type: COMPARATOR
Intervention: 3D vision system
Number of subjects: 29